摘要
目的比较经皮腔内血管成形术(percutaneous transluminal angioplasty,PTA)与单纯药物治疗膝下动脉缺血的临床疗效。方法选择膝下动脉缺血患者73例,分为PTA治疗组37例和药物治疗组36例,分别记录患者治疗前和治疗后1、3、6、12、18和24个月踝肱指数(ankle brachial index,ABI)、跛行距离、血管通畅情况、静息痛及截肢情况,进行统计学分析,采用Kaplan-Meier曲线分析再通率和免截肢情况。结果 PTA治疗组治疗后1~24个月随访ABI均高于药物治疗组,到24个月时ABI仍高于药物治疗组(0.640±0.238 vs 0.500±0.152,P=0.038);PTA治疗组患者1和3个月跛行距离、1~18个月的静息痛改善幅度较药物治疗组明显(P<0.05,P<0.01);2组患者的免截肢生存曲线相似(P_(logrank)=0.618)。结论对于静息痛明显、严重间歇性跛行、急需改善症状的患者,PTA治疗将会获益更大,症状改善更为明显。
Objective To compare the clinical curative effects of PTA and simple pharmacotherapy for intrapopliteal artery ischemic disease.Methods Seventy-three patients with intrapopliteal artery ischemic disease were divided into PTA group(n=37)and pharmacotherapy group(n=36).Their ABI,claudication distance,vascular patency,rest pain and amputation rate were recorded and analyzed with SPSS 22.0 at months 1,3,6,12,18 and 24 respectively before and after treatment.The vascular patency and amputation rate were analyzed according to the Kaplan-Meier curve.Results The ABI was higher in PTA group than in pharmacotherapy group during the 1-24 months following up period after treatment,and was still higher in PTA group than in pharmacotherapy group at month 24 after treatment(0.640±0.238 vs0.500±0.152,P=0.038).The claudication distance was shorter and the rest pain was milder in PTA group than in pharmacotherapy group at months 1 and 3,and at months 1-18 respectively(P〈0.05,P〈0.01).No significant difference was found in amputation-free survival curves between the two groups(Plogrank=0.618).Conclusion The symptom improvement of PTA is better than that of pharmacotherapy for patients with severe rest pain or severe intermittent claudication.
作者
王晓
崔世军
谷涌泉
杨胜家
罗涛
Wang Xiao;Cu Shij un;Gu Yongquan;Yang Shengjia;Luo Tao(Department of Vascular Surgery ,Affiliated Xuanwu Hospital of Capital Medical University, Beij ing , 100053, China)
出处
《中华老年心脑血管病杂志》
CAS
北大核心
2018年第5期458-461,共4页
Chinese Journal of Geriatric Heart,Brain and Vessel Diseases
关键词
血管成形术
经腔
经皮冠状动脉
药物疗法
下肢
动脉硬化
angioplasty
transluminal
percutaneous coronary
drug therapy
lower extremity
arte-riosclerosis